<SEC-DOCUMENT>0001213900-21-000810.txt : 20210107
<SEC-HEADER>0001213900-21-000810.hdr.sgml : 20210107
<ACCEPTANCE-DATETIME>20210107085937
ACCESSION NUMBER:		0001213900-21-000810
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		5
CONFORMED PERIOD OF REPORT:	20210101
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210107
DATE AS OF CHANGE:		20210107

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NEUROONE MEDICAL TECHNOLOGIES Corp
		CENTRAL INDEX KEY:			0001500198
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				270863354
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-54716
		FILM NUMBER:		21513085

	BUSINESS ADDRESS:	
		STREET 1:		7599 ANAGRAM DR
		CITY:			EDEN PRAIRIE
		STATE:			MN
		ZIP:			55344
		BUSINESS PHONE:		(952) 426-1383

	MAIL ADDRESS:	
		STREET 1:		7599 ANAGRAM DR
		CITY:			EDEN PRAIRIE
		STATE:			MN
		ZIP:			55344

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Original Source Entertainment, Inc.
		DATE OF NAME CHANGE:	20100830
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ea132820-8k_neuroone.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WASHINGTON,
D.C.&nbsp; 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FORM
8-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CURRENT
REPORT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pursuant
to Section 13 or 15(d) of The Securities Exchange Act of 1934</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date
of Report (Date of Earliest Event Reported): <B>January 1, 2021</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NeuroOne
Medical Technologies Corporation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of registrant as specified in its charter)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0; width: 32%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0; width: 32%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>000-54716</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0; width: 32%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>27-0863354</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
    or other jurisdiction<BR>
of incorporation)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission
    File Number)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(IRS
    Employer<BR>
Identification No.)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>7599
Anagram Dr., Eden Prairie, MN 55344</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
of principal executive offices and zip code)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>952-426-1383</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registrant&rsquo;s
telephone number including area code)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>N/A</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registrant&rsquo;s
former name or former address, if changed since last report)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; width: 24px; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written
    communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; width: 24px; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting
    material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; width: 24px; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; width: 24px; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(b) of the Act:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; width: 34%; border-bottom: black 1.5pt solid; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title
    of each class</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; width: 1%; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; width: 32%; border-bottom: black 1.5pt solid; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Trading
    Symbol(s)</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; width: 1%; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; width: 32%; border-bottom: black 1.5pt solid; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name
    of each exchange on which registered</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
Growth Company &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;<B>&nbsp;</B></FONT></P>

<P STYLE="text-align: justify; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Item&nbsp;5.02</B></FONT> <FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. </B></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January&nbsp;7, 2021, NeuroOne Medical Technologies Corporation (the &ldquo;Company&rdquo;) announced that Ron McClurg (&ldquo;McClurg&rdquo;),
age 62, has been appointed to be the Chief Financial Officer of the Company, effective on January&nbsp;1, 2021. A copy of the
Company&rsquo;s news release announcing McClurg&rsquo;s appointment is attached hereto as Exhibit&nbsp;99.1 and is incorporated
herein by reference.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to joining the Company, from October 2003 to June 2019, Mr. McClurg served as Vice President - Finance &amp; Administration and
Chief Financial Officer of Incisive Surgical, Inc., a privately-held medical device manufacturer. From 1997 to 2002, Mr. McClurg
served as Chief Financial Officer and Treasurer of Wavecrest Corporation, a privately-held manufacturer of electronic test instruments
for the semiconductor industry. Prior to 1997, Mr. McClurg served as Chief Financial Officer for several publicly-held companies,
including Video Sentry Corporation, Insignia Systems, Inc., and Orthomet, Inc. Currently, he serves on the board of governors
of Biomagnetic Sciences, LLC.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>McClurg
Offer Letter</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 1, 2021 (the &ldquo;McClurg Start Date&rdquo;), the Company and McClurg entered into a written agreement concerning McClurg&rsquo;s
employment (the &ldquo;McClurg Contract&rdquo;). The McClurg Contract provides that McClurg will receive a $250,000 annual salary,
which amount is subject to review and may be adjusted based on the Company&rsquo;s normal performance review practices, and that
McClurg is eligible for an annual performance bonus up to twenty-five percent (25%) of McClurg&rsquo;s effective salary for the
applicable bonus year based on McClurg&rsquo;s performance and the Company&rsquo;s performance. McClurg will also be allowed to
participate in the benefits programs and arrangements available to the Company&rsquo;s employees, including paid vacation and
sick leave, contributory and non-contributory welfare and benefit plans, disability plans, and medical, death benefit and life
insurance plans for which McClurg is eligible under the terms of such plans.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the terms of the Company&rsquo;s 2017 Equity Incentive Plan (as such plan may be amended, modified or replaced, the &ldquo;Plan&rdquo;)
and the form of stock option agreement issued thereunder, on the McClurg Start Date, McClurg received a stock option (the &ldquo;Initial
Option Award&rdquo;) to purchase 180,000 shares of the Company&rsquo;s common stock (the &ldquo;Initial Shares&rdquo;), with an
exercise price of $1.57 per share. The Initial Option Award shall be subject to the following additional terms: (1) subject to
his continued employment with the Company and the terms of the Plan, twenty-five percent (25%) of the Initial Shares shall vest
and become exercisable on the one (1) year anniversary of the McClurg Start Date and the balance of the Initial Shares subject
to the Initial Option Award shall vest and become exercisable in equal monthly installments on the last day of each month over
the next thirty-six (36) months; and (2) upon the occurrence of a Change of Control (as defined in the Plan) all of the Initial
Shares subject to the Initial Option Award shall fully vest and become exercisable immediately prior to the effectiveness of such
Change in Control, subject to McClurg&rsquo;s continued employment with the Company as of such date and as further provided in
the terms and conditions of the McClurg Contract, the Initial Option Award and the Plan.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">McClurg
will be an at-will employee of the Company.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
copy of the McClurg Contract is attached hereto as Exhibit 10.1 and is incorporated herein by reference. The above description
of the material terms of the McClurg Contract is qualified in its entirety by reference to such exhibit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item&nbsp;9.01
Financial Statements and Exhibits.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(d)
Exhibits.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; width: 9%; border-bottom: black 1.5pt solid; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; width: 1%; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; width: 90%; border-bottom: black 1.5pt solid; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><A HREF="ea132820ex10-1_neuroone.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment Offer Letter, dated as of January 1, 2021, by and between Ron McClurg and the Company</FONT></A></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><A HREF="ea132820ex99-1_neuroone.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press release, dated January 7, 2021</FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNATURE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; vertical-align: top; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; vertical-align: bottom; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NEUROONE
    MEDICAL TECHNOLOGIES CORPORATION</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; vertical-align: top; width: 60%; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
    January 7, 2021</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; vertical-align: bottom; width: 4%; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; vertical-align: bottom; width: 36%; border-bottom: black 1.5pt solid; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    David Rosa</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; vertical-align: top; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; vertical-align: bottom; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; vertical-align: bottom; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">David
    Rosa</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; vertical-align: top; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; vertical-align: bottom; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; vertical-align: bottom; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>ea132820ex10-1_neuroone.htm
<DESCRIPTION>EMPLOYMENT OFFER LETTER, DATED AS OF JANUARY 1, 2021, BY AND BETWEEN RON MCCLURG AND THE COMPANY
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ex10-1_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-variant: small-caps">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-variant: small-caps">7599
Anagram Drive</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-variant: small-caps">Eden
Prairie, Minnesota 55344</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">January 1, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ron McClurg</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3155 Olive Lane North</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Plymouth, Minnesota 55447</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Dear Ron:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are pleased to
offer you employment with <FONT STYLE="font-variant: small-caps">NeuroOne Medical Technologies Corporation,</FONT> a Delaware
corporation (the <B><I>&ldquo;Company&rdquo;</I></B>). The terms of your offer are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Your initial position
with us will be as Chief Financial Officer of the Company. Beginning January 1, 2021 (the <B><I>&ldquo;Effective Date&rdquo;</I></B>),
your annual base salary will be $250,000, paid in equal monthly installments in accordance with our normal payroll procedures.
In addition, you will be eligible to earn an annual performance bonus up to twenty-five percent (25%) of your effective salary
for the applicable bonus year based upon your performance and the Company&rsquo;s performance, subject to payroll deductions and
all required withholdings (the <B><I>&ldquo;Performance Bonus&rdquo;</I></B>).&nbsp; You must be an employee in good standing
on the Performance Bonus payment date to earn and be eligible to receive a Performance Bonus.&nbsp; The Company&rsquo;s Board
of Directors (the <B><I>&ldquo;Board&rdquo;</I></B>) (or the Compensation Committee of the Board) will determine whether you have
earned the Performance Bonus and the amount of any Performance Bonus based upon achievement of milestones which shall be determined
in sole discretion of the Board (or the Compensation Committee of the Board). Your annual base salary amount shall be subject
to review and may be adjusted based upon the Company&rsquo;s normal performance review practices. During your employment, you
will be allowed to participate in the benefit programs and arrangements that we make available to our employees, including paid
vacation and sick leave, contributory and non-contributory welfare and benefit plans, disability plans, and medical, death benefit
and life insurance plans for which you are eligible under the terms of those plans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to the terms
of Company&rsquo;s 2017 Equity Incentive Plan (as such plan may be amended, modified or replaced, the <B><I>&ldquo;Plan&rdquo;</I></B>)
and the form of stock option agreement issued thereunder, promptly following the Effective Date, the Company will issue you a
stock option (the <B><I>&ldquo;Initial Option Award&rdquo;</I></B>) to purchase 180,000 shares of the Company&rsquo;s common stock
(the <B><I>&ldquo;Initial Shares&rdquo;</I></B>). The Initial Option Award shall include the following additional terms: (1) the
exercise price per share for the Initial Shares shall equal the fair market value of the Company&rsquo;s common stock on the date
of the grant of the Initial Option Award; (2) subject your continued employment with the Company and the terms and conditions
of the Plan, twenty-five percent (25%)&nbsp;of the Initial Shares shall vest and become exercisable on the one (1) year anniversary
of the Effective Date and the balance of the Initial Shares subject to the Initial Option Award shall vest and become exercisable
in equal monthly installments on the last day of each month over the next thirty-six (36)&nbsp;months; and (3) upon the occurrence
of a Change in Control (as defined in the Plan) all of the Initial Shares subject to the Initial Option Award shall fully vest
and become exercisable immediately prior to the effectiveness of such Change in Control, subject to your continued employment
with the Company as of each such date and as further provided in the terms and conditions of this Agreement, the Initial Option
Award and the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Your employment will
be subject to the terms of the Company&rsquo;s employee handbook (as amended from time to time), which will supplement this letter
agreement and is expressly incorporated by reference into this letter agreement. In addition, your job duties, title, responsibility
and reporting level, compensation and benefits, as well as personnel policies and procedures, are subject to change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Your employment is
effective as of the Effective Date. By signing this letter agreement, you acknowledge and agree that your employment with the
Company is &ldquo;at will,&rdquo; meaning that either you or the Company are entitled to terminate your employment at any time
for any reason, with or without cause. Although your job duties, title, compensation and benefits, as well as the Company&rsquo;s
personnel policies and procedures, may change from time to time, the &ldquo;at will&rdquo; nature of your employment may only
be changed in an express writing signed by you and the Company.&#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You are required,
as a condition to your employment with the Company, to sign the Company&rsquo;s standard Employee Proprietary Information, Inventions
Assignment and Non-Competition Agreement in the form attached hereto as <FONT STYLE="font-variant: small-caps"><U>Exhibit A</U></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In your work for the
Company, you are expected not to use or disclose any confidential information, including trade secrets, of any former employer
or other third party to whom you have an obligation of confidentiality. You are expected to use only that information which is
generally known and used by persons with training and experience comparable to your own, which is common knowledge in the industry
or otherwise legally in the public domain, or which is otherwise provided or developed by the Company. By execution of this letter
agreement, you hereby agree that you will not bring onto premises of the Company or use in your work for the Company any unpublished
documents or property (including but not limited to proprietary information) belonging to any former employer or other third party
that you are not authorized to use or disclose. By execution of this letter agreement, you hereby represent that you are able
to perform your job duties within these guidelines.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This letter agreement
and its attachments contain all of the terms of your employment with the Company and supersedes any prior understandings or agreements,
whether oral or written, between you and the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This letter agreement
may not be amended or modified except by an express written agreement signed by you and a duly authorized member of the Board.
The terms of this letter agreement shall be governed by and construed in accordance with the internal laws of the State of Minnesota,
without regard to its principles of conflicts of laws. By signing this letter agreement you irrevocably submit to the exclusive
jurisdiction of the state and federal courts of the State of Minnesota for the purpose of any suit, action, proceeding or judgment
relating to or arising out of this letter agreement and the transactions contemplated hereby.&nbsp; BY SIGNING THIS LETTER AGREEMENT
YOU ALSO WAIVE ANY RIGHT TO REQUEST A TRIAL BY JURY IN ANY LITIGATION WITH RESPECT TO THIS LETTER AGREEMENT AND REPRESENT THAT
COUNSEL HAS BEEN CONSULTED SPECIFICALLY AS TO THIS WAIVER.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We hope that you find
the foregoing terms acceptable. You may indicate your agreement with these terms and accept this offer by signing and dating duplicate
original copies of this letter agreement and the enclosed Employee Proprietary Information, Inventions Assignment and Non-Competition
Agreement and returning them to me. As required by law, your employment with the Company is also contingent upon you providing
legal proof of your identity and authorization to work in the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 189pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">Sincerely, </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0in">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left"><FONT STYLE="font-size: 10pt; font-variant: small-caps"><B>NeuroOne Medical Technologies
    Corporation</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 5%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 35%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; padding-right: -9pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; padding-right: -9pt; text-align: justify"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding-right: -9pt; text-align: justify"><FONT STYLE="font-size: 10pt">/s/ Dave
    Rosa</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: -9pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: -9pt; text-align: justify"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="padding-right: -9pt; text-align: justify"><FONT STYLE="font-size: 10pt">Dave Rosa</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: -9pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: -9pt; text-align: justify"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="padding-right: -9pt; text-align: justify"><FONT STYLE="font-size: 10pt">President and Chief Executive Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>ACKNOWLEDGEMENT AND ACCEPTANCE</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">I have read and accept
this employment offer. By signing this letter agreement, I represent and warrant to the Company that I am under no contractual
commitments inconsistent with my obligations to the Company. Further, in consideration of my employment, I agree that, unless
a shorter period of limitations applies, any claim, suit, action or other proceeding arising out of my employment or the termination
of my employment, including but not limited to claims arising under state or federal civil rights statutes, must be brought or
asserted by me within six (6) months of the event giving rise to the claim or be forever barred. I expressly waive any longer
statute or other period of limitations to the contrary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 40%"><FONT STYLE="font-size: 10pt">/s/ Ron McClurg</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 20%">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 40%"><FONT STYLE="font-size: 10pt">Dated: January 1, 2021</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt; font-variant: small-caps">Ron McClurg</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B><U>EXHIBIT
A</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B><U>Employee
Proprietary Information, Inventions<BR>
Assignment AND NON-COMPETITION Agreement</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">THIS EMPLOYEE PROPRIETARY
INFORMATION, INVENTIONS ASSIGNMENT AND NON-COMPETITION AGREEMENT (this <B><I>&ldquo;Agreement&rdquo;</I></B>) is made as of the
date set forth below between <FONT STYLE="font-variant: small-caps">NeuroOne Medical Technologies Corporation</FONT>, a Delaware
corporation (the <B><I>&ldquo;Company&rdquo;</I></B>), and the undersigned employee of the Company (<B><I>&ldquo;Employee&rdquo;</I></B>).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Agreement confirms
certain terms of Employee&rsquo;s employment with the Company, which Employee acknowledges are a material part of the consideration
for Employee&rsquo;s employment by the Company, and the compensation received by Employee from the Company from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>1. <FONT STYLE="font-variant: small-caps">Definitions.
</FONT></B>The following capitalized terms used in this Agreement shall have the following meanings:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(a) <I>&ldquo;Company
Documents and Materials&rdquo; </I></B>means documents or other media, whether in tangible or intangible form, that contain or
embody Proprietary Information or any other information concerning the business, operations or plans of the Company, whether such
documents or media have been prepared by Employee or by others. Company Documents and Materials include, without limitation, blueprints,
drawings, photographs, charts, graphs, notebooks, tests, test results, experiments, customer lists, computer disks, tapes or printouts,
sound recordings and other printed, electronic, typewritten or handwritten documents or information, sample products, prototypes
and models.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(b) <I>&ldquo;Inventions&rdquo;
</I></B>means, without limitation, all software programs or subroutines, source or object code, algorithms, improvements, inventions,
works of authorship, trade secrets, technology, designs, formulas, ideas, processes, techniques, know-how and data, whether or
not patentable or copyrightable, made or discovered or conceived or reduced to practice or developed by Employee, either alone
or jointly with others.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(c) <I>&ldquo;Proprietary
Information&rdquo;</I></B> means information that was or will be developed, created, or discovered by or on behalf of the Company,
or which became or will become known to, or was or is conveyed to the Company, which has commercial value in the Company&rsquo;s
business, whether or not patentable or copyrightable, including, without limitation, information about software programs and subroutines,
source and object code, algorithms, trade secrets, designs, technology, know-how, processes, data, ideas, techniques, inventions,
works of authorship, formulas, business and product development plans, customer lists, terms of compensation and performance levels
of the Company&rsquo;s employees and consultants, the Company&rsquo;s customers and other information concerning the Company&rsquo;s
actual or anticipated business, research or development, or which is received in confidence by or for the Company from any other
person or entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>2. <FONT STYLE="font-variant: small-caps">Confidentiality
of Proprietary Information.</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(a) Nature of Information.
</B>Employee understands that the Company possesses and will possess Proprietary Information which is important to its business.
Employee understands that Employee&rsquo;s engagement creates a relationship of confidence and trust between the Company and Employee
with respect to Proprietary Information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(b) Property of the
Company.</B> Employee acknowledges and agrees that all Company Documents and Materials, Proprietary Information and all patents,
patent rights, copyrights, trade secret rights, trademark rights and other rights (including, without limitation, intellectual
property rights) anywhere in the world in connection therewith is and shall be the sole property of the Company. Employee hereby
assigns to the Company any and all rights, title and interest Employee may have or acquire in the Proprietary Information or any
Company Documents and Materials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps">Exhibit A - </FONT><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(c) Confidentiality.
</B>At all times, both during the term of Employee&rsquo;s engagement by the Company and after Employee&rsquo;s termination, Employee
shall keep in confidence and trust and shall not use or disclose any Proprietary Information or anything relating to it without
the prior written consent of the President or other duly designated officer of the Company, except as may be necessary in the
ordinary course of performing Employee&rsquo;s duties for the Company; provided, however, that Employee shall have no such obligation
with respect to Proprietary Information that (i) was already known to Employee at the time of its disclosure to Employee by or
on behalf of the Company, as evidenced by written records (ii) at the time of disclosure to Employee was generally available to
the public or otherwise in the public domain, or (iii) subsequent to such disclosure becomes generally available to the public
without fault on Employee&rsquo;s part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(d) Compelled Disclosure.
</B>In the event that Employee is requested in any proceeding to disclose any Proprietary Information, Employee shall give the
Company prompt notice of such request so that the Company may seek an appropriate protective order. If, in the absence of a protective
order, Employee is nonetheless compelled by any court or tribunal of competent jurisdiction to disclose Proprietary Information,
Employee may disclose such information without liability hereunder; provided, however, that Employee gives the Company notice
of the Proprietary Information to be disclosed as far in advance of its disclosure as is practicable and uses Employee&rsquo;s
best efforts to obtain assurances that confidential treatment will be accorded to such Proprietary Information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(e) Records.</B>
Employee agrees to make and maintain adequate and current written records, in a form specified by the Company, of all Inventions,
trade secrets and works of authorship assigned or to be assigned to the Company pursuant to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(f) Handling of the
Company Documents and Materials.</B> Employee agrees that during Employee&rsquo;s employment by the Company, Employee shall not
remove any Company Documents and Materials from the business premises of the Company or deliver any Company Documents and Materials
to any person or entity outside the Company, except as Employee may be required to do in connection with performing the duties
of Employee&rsquo;s employment. Employee further agrees that, immediately upon the termination of Employee&rsquo;s employment
by Employee or by the Company for any reason, or during Employee&rsquo;s employment if so requested by the Company, Employee shall
return all Company Documents and Materials, apparatus, equipment and other physical property, or any reproduction of such property,
excepting only (i) Employee&rsquo;s personal copies of personnel records and records relating to Employee&rsquo;s compensation;
and (ii) Employee&rsquo;s copy of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>3. <FONT STYLE="font-variant: small-caps">Inventions.</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(a) Disclosure. </B>Employee
shall promptly disclose in writing to Employee&rsquo;s immediate supervisor or to such other person designated by the Company
all Inventions made during the term of Employee&rsquo;s employment. Employee shall also disclose to Employee&rsquo;s immediate
supervisor or such designee all Inventions made, discovered, conceived, reduced to practice or developed by Employee either alone
or jointly with others, within six (6) months after the termination of Employee&rsquo;s employment with the Company which resulted,
in whole or in part, from Employee&rsquo;s prior employment by the Company. Such disclosures shall be received by the Company
in confidence, to the extent such Inventions are not assigned to the Company pursuant to subsection (b) below, and do not extend
the assignments made in such subsection.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(b) Assignment of
Inventions to the Company.</B> Except as provided in Sections 3(c) and 3(d), Employee agrees that all Inventions which Employee
makes, discovers, conceives, reduces to practice or develops (in whole or in part, either alone or jointly with others) during
Employee&rsquo;s employment, including, but&nbsp;not limited&nbsp;to,&nbsp;conceptions or ideas derived prior to employment&nbsp;and
reduced to practice or developed (in whole or in part, either alone or jointly with others) during employment, shall be the sole
property of the Company to the&nbsp;maximum extent permitted by law and Employee agrees to assign and hereby does assign to the
Company all right&nbsp;title and interest to the Inventions. &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps">Exhibit A - </FONT><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(c) Works Made for
Hire.</B> Employee agrees that the Company shall be the sole owner of all patents, patent rights, copyrights, trade secret rights,
trademark rights and all other intellectual property or other rights in connection with Inventions. Employee further acknowledges
and agrees that such Inventions, including, without limitation, any computer programs, programming documentation and other works
of authorship, are &ldquo;works made for hire&rdquo; for purposes of the Company&rsquo;s rights under copyright laws. Employee
hereby assigns to the Company any and all rights, title and interest Employee may have or acquire in such Inventions. If in the
course of Employee&rsquo;s employment with the Company, Employee incorporates into a Company product, process or a machine a prior&nbsp;Invention
or improvement owned by Employee or in which Employee has an interest, and listed in Exhibit 1,&nbsp;the Company is hereby granted
and shall have a non-exclusive, royalty-free, irrevocable, perpetual, sublicensable, worldwide license to make, have made, modify,
use, market, sell and distribute such prior Invention as part of or in connection with such product process or machine.&nbsp;
Pursuant to Section 3(d), if in the course of Employee&rsquo;s employment with the Company, Employee incorporates into a Company
product, process or a machine a prior&nbsp;Invention or improvement owned by Employee or in which Employee has an interest, but
not listed in Exhibit 1, Employee agrees to assign and hereby does assign all rights and interest in the Invention to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(d) List of Inventions.
</B>Employee has attached hereto as Exhibit 1 a complete list of all Inventions or improvements to which Employee claims ownership
or in which Employee has an interest and that Employee desires to remove from the operation of this Agreement. Employee acknowledges
and agrees that such list is complete. If no such list is attached to this Agreement or such Exhibit has not been completed and
signed by Employee, Employee represents to the Company and agrees that Employee has no such Inventions or improvements at the
time of signing this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(e) Cooperation.
</B>Employee agrees to perform, during and after Employee&rsquo;s employment, all acts deemed necessary or desirable by the Company
to permit and assist it, at the Company&rsquo;s expense, in further evidencing and perfecting the assignments made to the Company
under this Agreement and in obtaining, maintaining, defending and enforcing patents, patent rights, copyrights, trademark rights,
trade secret rights or any other rights in connection with such Inventions and improvements in any and all countries. Such acts
may include, without limitation, execution of documents and assistance or cooperation in legal proceedings. Employee hereby irrevocably
designates and appoints the Company and its duly authorized officers and agents, as Employee&rsquo;s agents and attorney-in-fact,
coupled with an interest, to act for and on Employee&rsquo;s behalf and in Employee&rsquo;s place and stead, to execute and file
any documents, applications or related findings and to do all other lawfully permitted acts to further the purposes set forth
above in this Section, including, without limitation, the perfection of assignment and the prosecution and issuance of patents,
patent applications, filing with the FDA, copyright applications and registrations, trademark applications and registrations or
other rights in connection with such Inventions and improvements with the same legal force and effect as if executed by Employee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(f) Assignment or
Waiver of Moral Rights.</B> Any assignment of copyright hereunder (and any ownership of a copyright as a work made for hire) includes
all rights of paternity, integrity, disclosure and withdrawal and any other rights that may be known as or referred to as &ldquo;Moral
Rights&rdquo; (collectively, <B><I>&ldquo;Moral Rights&rdquo;</I></B>). To the extent such Moral Rights cannot be assigned under
applicable law and to the extent the following is allowed by the law in the various countries where Moral Rights exist, Employee
hereby waives such Moral Rights and consents to any action of the Company that would violate such Moral Rights in the absence
of such consent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(g) Holdover Assignment.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i) Employee agrees
to, after the termination of Employee&rsquo;s employment with the Company for any reason, (1) disclose immediately to the Company
all Inventions, patentable or not; (2) assist, at the Company&rsquo;s expenses such applications for United States patents and
foreign patents covering such Inventions as the Company may request; (3) assign to the Company without further compensation to
Employee the entire title and rights to all such Inventions and applications that Employee may have, and (4) execute, acknowledge,
deliver, or act as otherwise necessary at the request of the Company all such papers, including but not limited to patent applications,
assignments, power of attorney, as necessary to secure the Company the fully rights to such Inventions and applications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii) The Inventions
which shall come under this Section 3(g) shall include all Inventions that (1) Employee conceives, reduces to practice, or otherwise
makes or develops, either solely or jointly with others, within one year after the termination of Employee&rsquo;s employment
with the Company; and (2) are in any way based on any trade secret or confidential or proprietary information that Employee learned
during employment at the Company; or result from any work performed by Employee for the Company; or are in any way related to
the subject matter or activities of Employee&rsquo;s employment at the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps">Exhibit A - </FONT><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>4. <FONT STYLE="font-variant: small-caps">Non-Solicitation
or Hire of Company Employees.</FONT></B> During the term of Employee&rsquo;s employment and for one (1) year thereafter, Employee
shall not encourage or solicit any employee of the Company to leave the Company for any reason or to accept employment with any
other person or entity. As part of this restriction, Employee shall not (a) interview or provide any input to any third party
regarding any such person during such time period, or (b) retain or hire in any capacity, either individually or for any company
by which Employee may be employed or with which Employee may be affiliated, any person who is or was employed by the Company at
any time during the time of Employee&rsquo;s employment with Company and six (6) months after the termination of Employee&rsquo;s
employment with the Company. Notwithstanding the foregoing, the restrictions of this Section shall not apply with respect to the
<I>bona fide</I> hiring and firing of the Company personnel to the extent such acts are part of Employee&rsquo;s duties for the
Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>5. <FONT STYLE="font-variant: small-caps">Non-Solicitation
of Non-Employees.</FONT></B> During the term of this Agreement and for one (1) year thereafter, Employee shall not interfere with
or attempt to impair the relationship between the Company and any of its non-employee consultants and advisors or customers, nor
shall Employee attempt, directly or indirectly, to solicit, entice, hire or otherwise induce any non-employee consultant or advisor
or customer of the Company to terminate association with Company</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>6. <FONT STYLE="font-variant: small-caps">Non-Competition.
</FONT></B>During the term of Employee&rsquo;s employment and for one (1) year thereafter, Employee shall not, with or without
consideration, render services in any capacity to any person, business, firm or the Company engaged in any business competitive
with the business conducted by the Company at the time of Employee&rsquo;s employment with the Company, or the termination of
Employee&rsquo;s employment. Employee shall not become interested in any such business involved in competitive activities with
the Company, either directly or indirectly, as partner, stockholder, principal, member, employee, agent, trustee, consultant,
or any other relationship or capacity; provided, however, that such restriction shall not apply with respect to a less than or
equal to a one percent (1%) of an entity which is publicly traded and listed on a recognized securities exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>7. <FONT STYLE="font-variant: small-caps">Reasonableness
of Terms.</FONT></B> The Company and Employee agree that the terms contained in Sections 2-6 of this Agreement are reasonable
in all respects and that the restrictions contained therein are designed to ensure that Employee does not engage in unfair competition
with the Company. In the event a court determines that any of the terms or provisions of this Agreement are unreasonable, the
court may limit the application of any provision or term, or modify any provision or term, and proceed to enforce this Agreement
as so limited or modified.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>8. <FONT STYLE="font-variant: small-caps">Remedies.
</FONT></B>Employee acknowledges that a violation of the terms of this Agreement may give rise to irreparable injury to the Company
inadequately compensable in damages, and accordingly, agrees that the Company may seek injunctive relief against such breach or
threatened breach, in addition to any other legal remedies which may be available, including recovery of monetary damages. In
any action successfully brought by the Company to enforce the rights of the Company against Employee under this Agreement, the
Company shall also be entitled to recover reasonable attorneys&rsquo; fees and costs of the action, and the period of the restrictions
above shall be deemed to commence upon the entry of the court&rsquo;s order for relief.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>9. <FONT STYLE="font-variant: small-caps">General.</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(a) Severability.
</B>Employee agrees that if one or more provisions of this Agreement are held to be unenforceable under applicable law, such provisions
shall be excluded from this Agreement and the balance of the Agreement shall be interpreted as if such provision were so excluded
and shall be enforceable in accordance with its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(b) Authorization
to Notify New Employer. </B>Employee hereby authorizes the Company to notify Employee&rsquo;s new employer about Employee&rsquo;s
rights and obligations under this Agreement following the termination of Employee&rsquo;s employment with the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps">Exhibit A - </FONT><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(c) Entire Agreement.
</B>This Agreement sets forth the entire agreement and understanding between the Company and Employee relating to the subject
matter herein and supersedes all prior discussions between them and any and all statements made by any officer, employee or representative
of the Company regarding the Company&rsquo;s financial condition or future prospects. Employee understands and acknowledges that,
except as set forth in this Agreement and in the offer letter from the Company to Employee, (i) no other representation or inducement
has been made to Employee, (ii) Employee has relied on Employee&rsquo;s own judgment and investigation in accepting Employee&rsquo;s
employment with the Company, and (iii) Employee has not relied on any representation or inducement made by any officer, employee
or representative of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(d) Amendment.</B>
No modification of or amendment to this Agreement nor any waiver of any rights under this Agreement shall be effective unless
in a writing signed by the President of the Company and Employee. Employee understands and agrees that any subsequent change or
changes in Employee&rsquo;s duties, salary or compensation shall not affect the validity or scope of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(e) Effective Date
and Binding Effect.</B> This Agreement shall be effective as of the first day of Employee&rsquo;s employment with the Company
and shall be binding upon Employee, Employee&rsquo;s heirs, executor, assigns and administrators and shall inure to the benefit
of the Company, its subsidiaries, successors and assigns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(f) Governing Law;
Consent to Jurisdiction, Waiver of Jury Trial.</B> This Agreement shall be governed by and construed in accordance with the internal
laws of the State of Minnesota, without regard to its principles of conflicts of laws. Each of the parties hereto irrevocably
submits to the exclusive jurisdiction of the courts of the State of Minnesota located and United States District Courts in the
State of Minnesota for the purpose of any suit, action, proceeding or judgment relating to or arising out of this Agreement and
the transactions contemplated hereby.&nbsp; Service of process in connection with any such suit, action or proceeding may be served
on each party hereto anywhere in the world by the same methods as are specified for the giving of notices under this Agreement.&nbsp;
Each of the parties hereto irrevocably consents to the jurisdiction of any such court in any such suit, action or proceeding and
to the laying of venue in such court.&nbsp; Each party hereto irrevocably waives any objection to the laying of venue of any such
suit, action or proceeding brought in such courts and irrevocably waives any claim that any such suit, action or proceeding brought
in any such court has been brought in an inconvenient forum.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">EMPLOYEE HAS READ THIS
AGREEMENT CAREFULLY AND UNDERSTANDS AND ACCEPTS THE OBLIGATIONS WHICH IT IMPOSES UPON EMPLOYEE WITHOUT RESERVATION. NO PROMISES
OR REPRESENTATIONS HAVE BEEN MADE TO EMPLOYEE TO INDUCE EMPLOYEE TO SIGN THIS AGREEMENT. EMPLOYEE SIGNS THIS AGREEMENT VOLUNTARILY
AND FREELY.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>THE COMPANY:</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>EMPLOYEE:</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: left"><FONT STYLE="font-size: 10pt; font-variant: small-caps">NeuroOne Medical Technologies
    Corporation</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; width: 5%; text-align: justify"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 35%; text-align: justify"><FONT STYLE="font-size: 10pt">/s/ Dave Rosa</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 20%; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 40%; text-align: justify"><FONT STYLE="font-size: 10pt">/s/ Ron McClurg</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Dave Rosa</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Print Name: <FONT STYLE="font-variant: small-caps">Ron McClurg</FONT></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">President and CEO</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Date: January 1, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: justify">&nbsp;<FONT STYLE="font-variant: small-caps">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps">Exhibit A - </FONT><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>ea132820ex99-1_neuroone.htm
<DESCRIPTION>PRESS RELEASE, DATED JANUARY 7, 2021
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white">&nbsp;<IMG SRC="ex99-1_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NeuroOne
Medical Technologies Corporation Appoints Ronald McClurg, <BR>
Experienced Financial Industry Executive, as Chief Financial Officer</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Eden
Prairie, MN &ndash; January 7, 2021&ndash; </B><U>NeuroOne Medical Technologies Corporation</U> (OTCQB: NMTC; NeuroOne), a medical
technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders,
announces today the appointment of Ronald McClurg, an experienced senior financial industry executive, as Chief Financial Officer
of NeuroOne Medical Technologies Corporation. Mr. McClurg has over 30 years of financial leadership experience with both public
and privately held companies. He has held the role of CFO for a number of public companies including Orthomet, Inc., Video Sentry
Corporation, and Insignia Systems, Inc. He also held the role of CFO at Incisive Surgical, a privately held medical device company.
He began his career in public accounting with Ernst and Young, where he earned his CPA certificate.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Dave
Rosa, President and CEO, of NeuroOne, says, &ldquo;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Over
the past quarter the Company has made great progress in achieving key milestones and building our infrastructure. With our
future goal to uplist to a major national securities exchange, it became critical to add a seasoned senior financial
executive such as Ron. His broad experience with both public and private companies as well as his familiarity with medical
device companies make him an ideal fit for the role of CFO at NeuroOne. We are very fortunate to have him as part of the
NeuroOne family and look forward to working with him.&rdquo;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
McClurg states, &ldquo;I&rsquo;m excited to join the <FONT STYLE="background-color: white">NeuroOne</FONT> team because I believe in
the Company&rsquo;s growth strategy to improve outcomes for patients suffering from neurological disorders and enhance shareholder value.
I feel that my skills and experience will complement those of the rest of the <FONT STYLE="background-color: white">NeuroOne</FONT>
leadership team.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">NeuroOne
received FDA clearance for its Evo cortical electrode technology in November 2019. It plans to submit a second 510(k)
application for its sEEG electrode technology in the first half of 2021 to bolster its product portfolio for use in
recording, monitoring and stimulating brain tissue for up to 30 days. In addition, the Company continues developing
therapeutic electrodes for use in Parkinson&rsquo;s Disease, epilepsy and back pain due to failed back surgery.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In
partnership with Mayo Clinic, Wisconsin Alumni Research Foundation (WARF) and other prominent academic medical centers, the Company
began developing its cortical electrode technology in 2015. The Company initially focused its efforts on the epilepsy and intraoperative
tumor monitoring markets. NeuroOne intends to continue to develop the technology for use in therapeutic applications for Parkinson&rsquo;s
disease, epilepsy and pain management due to failed back surgery procedures.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In
July 2020, NeuroOne executed a distribution and development agreement with Zimmer Biomet that provides exclusive rights to distribute
NeuroOne&rsquo;s current Evo cortical electrodes and its sEEG electrode product line once it has received FDA clearance.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
NeuroOne</B><BR>
NeuroOne Medical Technologies Corporation is a developmental stage company committed to providing minimally invasive and hi-definition
solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson&rsquo;s disease,
dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve
patient outcomes and reduce procedural costs. For more information, visit <U>https://www.n1mtc.com</U>.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Forward
Looking Statements</B><BR>
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended. Except for statements of historical fact, any information
contained in this presentation may be a forward-looking statement that reflects NeuroOne&rsquo;s current views about future events
and are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity,
performance or achievements to be materially different from the information expressed or implied by these forward-looking statements.
In some cases, you can identify forward-looking statements by the words &ldquo;may,&rdquo; &ldquo;might,&rdquo; &ldquo;will,&rdquo;
&ldquo;could,&rdquo; &ldquo;would,&rdquo; &ldquo;should,&rdquo; &ldquo;expect,&rdquo; &ldquo;intend,&rdquo; &ldquo;plan,&rdquo; &ldquo;objective,&rdquo;
&ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo; &ldquo;estimate,&rdquo; &ldquo;predict,&rdquo; &ldquo;project,&rdquo; &ldquo;potential,&rdquo;
&ldquo;target,&rdquo; &ldquo;seek,&rdquo; &ldquo;contemplate,&rdquo; &ldquo;continue&rdquo; and &ldquo;ongoing,&rdquo; or the negative of
these terms, or other comparable terminology intended to identify statements about the future. Forward-looking statements may
include statements regarding the timing and extent of product launch and commercialization of the technology, business strategy,
market size, potential growth opportunities, plans for product applications and product development, future operations, future
efficiencies, and other financial and operating information. Although NeuroOne believes that we have a reasonable basis for each
forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known
by us and our expectations of the future, about which we cannot be certain. Our actual future results may be materially different
from what we expect due to factors largely outside our control, including risks that the Company may not be able to successfully
uplist to a national securities exchange; risks that the partnership with Zimmer Biomet may not facilitate the commercialization
or market acceptance of our technology; risks that our sEEG electrodes may not be ready for commercialization in a timely manner
or at all; risks that our technology will not perform as expected based on results of our pre-clinical and clinical trials, our
ability to raise additional funds, uncertainties inherent in the development process of our technology, changes in regulatory
requirements or decisions of regulatory authorities, the size and growth potential of the markets for our technology, clinical
trial patient enrollment, the results of clinical trials, our ability to protect our intellectual property rights and other risks,
uncertainties and assumptions, including those described under the heading &ldquo;Risk Factors&rdquo; in our filings with the Securities
and Exchange Commission. These forward-looking statements speak only as of the date of this press release and NeuroOne undertakes
no obligation to revise or update any forward-looking statements for any reason, even if new information becomes available in
the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investor
Relations Contact</B>:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kelly
Novak</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Perspective
Communications<BR>
kellyn@n1mtc.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Caution:
Federal law restricts this device to sale by or on the order of a physician&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SOURCE:&nbsp;</B>NeuroOne
Medical Technologies Corporation</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>ex10-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex10-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  G .X# 2(  A$! Q$!_\0
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%46Y__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  T 1,# 2(  A$! Q$!_\0
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MVEW:)>16^H&Q_H/_ ."DW_!,?X8?\%!_!FES7FIK\/\ XT^";*[MO ?Q*M[
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1%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
